About us Contacts Drug interactions: 390 212
Drug search by name

PCE Dispertab and Upadacitinib

Determining the interaction of PCE Dispertab and Upadacitinib and the possibility of their joint administration.

Check result:
PCE Dispertab <> Upadacitinib
Relevance: 03.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.

Professional:

MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.

MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.

References
  • "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

Upadacitinib

Generic Name: upadacitinib

Brand name: Rinvoq

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction